<DOC>
	<DOCNO>NCT02571556</DOCNO>
	<brief_summary>To evaluate safety efficacy ocular iontophoresis dexamethasone phosphate ophthalmic solution , EGP-437® , use EyeGate® II Drug Delivery System ( EGDS ) patient undergone cataract surgery implantation posterior chamber intraocular lens ( IOL )</brief_summary>
	<brief_title>OPEN-LABEL , MULTI-CENTER , PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS ( IOL )</brief_title>
	<detailed_description>This Phase 1b/2a , open-label , multi-site study , total 20 eye 20 patient enrol . Patients undergone unilateral cataract surgery implantation posterior chamber monofocal intraocular lens ( IOL ) interest participate study provide informed consent form prior screen . Screening/Baseline procedure include best correct visual acuity ( BCVA ) , slit lamp examination , conjunctival injection , intraocular pressure ( IOP ) tonometry use determine eligibility prior cataract surgery Day 0 . Eligible subject undergo iontophoresis treatment immediately post-cataract surgery Day 0 Day 7 , return clinic examination Days 1 , 14 , 28 .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Have undergone unilateral cataract extraction implantation monofocal IOL time enrollment 2 . Age 18 85 year 3 . Receive , understand , sign copy write informed consent form 4 . Be able return study visit willing comply studyrelated instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>